Sabizabulin

Sabizabulin
Clinical data
Other namesVERU-111[1][2][3]
Legal status
Legal status
  • Investigational
Identifiers
  • [2-(1H-indol-3-yl)-1H-imidazol-5-yl]-(3,4,5-trimethoxyphenyl)methanone
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC21H19N3O4
Molar mass377.400 g·mol−1
3D model (JSmol)
  • COC1=CC(=CC(=C1OC)OC)C(=O)C2=CN=C(N2)C3=CNC4=CC=CC=C43
  • InChI=1S/C21H19N3O4/c1-26-17-8-12(9-18(27-2)20(17)28-3)19(25)16-11-23-21(24-16)14-10-22-15-7-5-4-6-13(14)15/h4-11,22H,1-3H3,(H,23,24)
  • Key:WQGVHOVEXMOLOK-UHFFFAOYSA-N

Sabizabulin is an investigational new drug that is being evaluated for the treatment of castration-resistant prostate cancer[4] and in SARS-CoV-2 (COVID-19) infections.[5] It is a tubulin polymerization inhibitor.[6][7]

Sabizabulin is chemical compound from the group of indole and imidazole derivatives that was first reported in 2012 by Dalton, Li, and Miller.[8]

  1. ^ "Substance Name: Sabizabulin". ChemIDplus. Retrieved 1 May 2022.
  2. ^ "Sabizabulin for COVID-19". Veru Inc. 14 January 2022. Retrieved 1 May 2022.
  3. ^ Cite error: The named reference NCT04842747 was invoked but never defined (see the help page).
  4. ^ Markowski MC, Tutrone R, Pieczonka C, Barnette KG, Getzenberg RH, Rodriguez D, et al. (July 2022). "A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor-targeting Agent". Clinical Cancer Research. 28 (13): 2789–2795. doi:10.1158/1078-0432.CCR-22-0162. PMC 9774054. PMID 35416959. S2CID 248128050.
  5. ^ rme (13 April 2022). "COVID-19: Krebsmittel Sabizabulin halbiert Sterberate bei schweren Erkrankungen" [COVID-19: Cancer drug Sabizabulin halves death rate in severe cases]. aerzteblatt.de. Retrieved 14 April 2022.
  6. ^ "Sabizabulin - Veru Healthcare". AdisInsight. Springer Nature Switzerland AG.
  7. ^ Mahmud F, Deng S, Chen H, Miller DD, Li W (December 2020). "Orally available tubulin inhibitor VERU-111 enhances antitumor efficacy in paclitaxel-resistant lung cancer". Cancer Letters. 495: 76–88. doi:10.1016/j.canlet.2020.09.004. PMC 7669640. PMID 32920198.
  8. ^ Li CM, Lu Y, Chen J, Costello TA, Narayanan R, Dalton MN, et al. (November 2012). "Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer". Pharmaceutical Research. 29 (11): 3053–3063. doi:10.1007/s11095-012-0814-5. PMC 3646298. PMID 22760659.